3 Barriers to Writing Automation & some Solutions
At the high-impact R&D end of life sciences, investment in technology is consciously linked to commercial priorities including innovation, efficiency and speed to market. There is an appreciation of the value of automation in administering and reporting on clinical trials, for instance. Here, smart use of technology to accelerate what would otherwise be labor intensive manual processes ensures that data representation (in form of documents/reports) is robust, bears close scrutiny, and doesn’t tie up more skilled resources than is absolutely necessary.
Writing (Medical, Regulatory, Safety, Scientific, CMC) is an art of science. Here comes the conflict of automation which is seen as “inhuman”. But as requirements are multiplying every day, how can companies manage the load without increasing resources or resorting to outsourcing or offshoring ?
All Writing teams want to spend time on “science” or “innovative projects” and not seen as a ‘cost center’. With these objectives and workload increasing, a case for technology enablement and automation is strong. So, what is holding companies back from investing in writing automation?
Below are three of the most common perceived barriers to technology-enabled writing automation, and how and why they should be addressed at the earliest.
1. A lack of “Writing” friendly enterprise solutions
Look at most other industries, especially those that are highly regulated, and use of IT systems tends to be highly evolved. That’s because organizations have long realized the inefficiency (in cost, time and resources) of using people to manually input data into core business systems, and then physically re-enter the information into adjacent systems in other departments.
In pharma, by contrast, “EDMS” and “Word” are the only and dominant tools provided to Authors. EDMS (whether on premise or cloud) may provide some help like versions, tracking, collaboration, but doesn’t address the bulk of manual heavy lifting that needs in Authoring. Same with WORD in spite of adding some plugins and other macros.
Some companies tried (and realized it didn’t helped) is Structured Content Authoring or XML editors. These are pretty good solutions from Tech point of view, but they are not intuitive to Writing world. Authors cannot relate (or may even get irritated sometimes) to terms these tools use like fragments, rules, components, variables, inheritance and so on.
In some cases, the issue is that Writing departments (whether medical or clinical or CMC) lack access to relevant technology expertise and knowledge, so they don’t have a picture of what’s available or what’s possible – including the scope for sourcing solutions and optimized business processes via cloud-based platforms and relationships with technology vendors. Meanwhile, larger companies which do have sufficient internal resources often believe that they need to build any tools themselves, something they may never get round to – especially if they haven’t tied down a proper business case & ROI
Given that some very intuitive and easy-to-integrate writing tools do exist out in the external market, with the precise purpose of assisting in improving writing efficiency, it seems surprising that sponsors do not make more use of them – especially as the time and cost savings associated with digital solutions are shown to exceed 60 per cent when compared with processes that rely on manual writing alone.,
2. Cost
For reasons mentioned earlier, writing does not tend to attract big budgets. This means that any investment in Writing management IT needs to be tightly targeted, and seen to deliver improved results with greater efficiency. If companies choose not to invest in transforming Writing activity, they risk spending more than they need to, and consuming too much time of busy people who have other more critical tasks to be getting on with.
While large companies, may question the cost/benefit trade-off of creating new automation aids, their internal development is not the only option. Taking advantage of a pre-existing pre-tested tool that’s ready to go today and accessible on demand via a software-as-a-service delivery model, changes the economics considerably – especially if there is no associated support burden, because the vendor takes care of everything.
3. Usability issues
Companies’ inertia when it comes to trying new technology often also comes down to an aversion to change, of having to behave in different ways which may require resource retraining. Tools’ intuitive ease of use is paramount in overcoming this very real barrier.,
In Writing, it follows that tools need to be easy and intuitive. If users were able to author, verify all data needed at one place, cross-check source data, content impact, simple work-flow– this could be transformational in itself. For writing departments, this improved user engagement ought to result in more complete and more reliable documents, captured in a timely fashion and reducing the burden on authors to chase up right data or information or any lack of clarity.
Why wait?
Looking for discrete tools which are very easy to adopt and use, and which alleviate a substantial manual administrative burden – are a good way for companies to test the potential of writing automation and amass some experience.
Embracing greater automation is going to be essential as writing/reporting requirements continue to multiply and grow, placing an ever greater strain on resources. Automation offers a way to cope with rising demand, and to simplify demanding routine tasks, as companies expand their product mix and market coverage, while maintaining regulatory compliance.
Yet, to take full advantage of the opportunities, companies need to overcome their historical barriers to technology adoption – and there is no time like the present.
Explore Topics
- Clinical Automation (8)
- IRT & Clinical Supplies (16)
- Labeling (14)
- Regulations (13)
- Regulatory Automation (12)
- Regulatory Biopharma (1)
- Regulatory Content Management (2)
- Regulatory Information Management (10)
- UDI (7)
- Writing (8)
Recent Blogs
- Why Impact Assessment is Criti…Regulatory Biopharma
- The Future of Regulatory Publi…Regulatory Automation
- Leveraging Automation for Regu…Regulatory Automation
Previous Post
Next Post
Related Posts